Form 4 for DGX Quest Diagnostics
Accepted 2022-03-09 00:00:00 ET · period of report 2022-03-07 · accession 0001022079-22-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-09 | 2022-03-07 | DGX | PREVOZNIK MICHAEL E | SVP, GC | A - Grant | $130.09 | +11.5K | 50.8K | +29% | +$1.50M | |
| 2022-03-09 | 2022-03-08 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $135.21 | -6,228 | 39.2K | -14% | -$842.1K | |
| 2022-03-09 | 2022-03-07 | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $130.09 | -5,316 | 45.5K | -10% | -$691.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-07 | A | A | 11,544 | $130.09 | 50,768 | D | — | — | (F1) Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d). |
| 2 | Common | Common Stock | 2022-03-08 | S | D | 6,228 | $135.21 | 39,224 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-07 | F | D | 5,316 | $130.09 | 45,452 | D | — | — | (F2) Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. |